GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

The vaccines business – where GSK is among the global leaders – did ... thanks to a surge in the sale of cancer drugs Jemperli and Zejula. To offer further encouragement, Dame Emma Walmsley, ...

GSK'227 targets B7-H3 ... Arexvy and Shingrix as well as a one-off credit from the Zejula royalty dispute in quarter 1. R&D grew 7%, broadly in line with sales as we invested in Phase 3 trials ...

GSK plc GSK reported fourth-quarter 2024 core ... it received approval in the EU in January 2024. Zejula sales fell 3% in the quarter. Though the drug’s U.S. sales were adversely impacted ...

Implementing an individualized starting dose (ISD) of niraparib (Zejula; GSK) reduced severe hematologic adverse event (AE) management costs by 48% compared with a fixed starting dose (FSD ...

GlaxoSmithKline, DualityBio, Latin American Cooperative Oncology Group, Mirati Therapeutics Inc., Eli Lilly and Company, Fox Chase Cancer Center, Merck Sharp & Dohme LLC, BeiGene, NeoImmuneTech ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...